CompletedNCT00650611

A Study of the Safety and Tolerability of Oral Ziprasidone in Children and Teens With Psychotic Disorders

Medication studyAges 10–17United StatesSchizophrenia

The study in practice

Understand this study

Listed age limits: 10 years to 17 years.

Listed locations: San Diego and 16 more locationsSee all locations and recruitment
Study phase: Phase 2

Study clarity

Study start dateDecember 2003

Recruitment status: Completed
Enrollment listed in the registry: 63
Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Sponsor type: Other organization
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 2
Locations: United States
Age range: From 10 Years to 17 Years
Official registry ID: NCT00650611
Official title: Show the full official title
A 27-Week Open-Label Trial To Characterize The Safety And Tolerability Of Orally Administered Ziprasidone In Children And Adolescent Subjects With Bipolar I Disorder (Manic Or Mixed), Schizophrenia Or Schizoaffective Disorder

Completed

San Diego · Altamonte Springs · Libertyville

9 more locations

FAQ

Who is behind this study?

The study sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Did this study involve medication?

Yes. The study involved medication, including Ziprasidone.

Who was this study for?

Listed age limits: 10 years to 17 years.